secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001493152-23-032278
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 5.02, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio appoints Mitchell Jones as CMO; grants inducement options and RSUs
-------------------------------------------------------------------------------

- Mitchell Jones, M.D., Ph.D., appointed Chief Medical Officer effective Sept 5, 2023.
- Herbert Slade ceased as CMO same date, will continue as consultant.
- Inducement grant: 75,000 options at $0.6897/share, 54,700 RSUs; vest over 3 years.
- Jones previously VP at Chemomab (CMMB), Finch Therapeutics (FNCH), Biora (BIOR); IBD expertise.
- Employment: base salary $415,000, target bonus 40%, severance provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315223032278/0001493152-23-032278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315223032278/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-032278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer